Abcam, ab275826, Human MAGEA1 knockout U-2 OS cell line

Size: 1000000Cells / vial / 2 x 1000000Cells / vial
MAGEA1 KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control available. Knockout achieved by CRISPR/Cas9 X = 5 bp deletion Frameshift: 99.99%. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:U-2 OS,
Species or organism:Human,
Tissue:Bone,
Form:LiquidSee storage information,
Knockout validation:Next Generation Sequencing,
Mutation description:Knockout achieved by CRISPR/Cas9 X = 5 bp deletion Frameshift: 99.99%,
Disease:Osteosarcoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-MAGEA1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions--196°C, -80°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
MAGEA1 also known as MAGE-1 is a member of the MAGE (Melanoma Antigen Gene) family of proteins. It has a molecular weight of approximately 39 kDa. MAGEA1 is expressed mainly in male germline tissues and in various cancer cells but not in adult somatic tissues. The protein functions mechanically by interacting with specific molecules in cells although detailed mechanisms are still under investigation.
Biological function summary
The protein encoded by MAGEA1 participates in cellular processes linked to cancer development and progression. It does not function as part of a larger complex but interacts directly with certain cellular pathways. In particular the expression of MAGEA1 is often associated with transformation events and uncontrolled cell proliferation underlining its role in oncogenesis.
Pathways
MAGEA1 plays roles in oncogenic and apoptotic pathways. It can influence the p53 signaling pathway important for cell cycle regulation and apoptosis. The interaction with other proteins such as p53 and potentially with the NF-kB pathway highlights how MAGEA1 might modulate the apoptotic response. MAGEA1 impacts cellular mechanisms by affecting apoptosis and proliferation through these pathways.
MAGEA1 is strongly related to cancer particularly melanoma and some other tumor types. Its expression in cancers makes MAGEA1 a target for cancer immunotherapy. MAGEA1 associates with proteins like p53 in certain cancers and can alter the tumor suppressive characteristics. Its role in these diseases presents MAGEA1 as a biomarker for cancer diagnosis and treatment adding clinical significance to its study.